Umberto Vitolo spends much of his time researching Internal medicine, Surgery, Gastroenterology, Lymphoma and Follicular lymphoma. Internal medicine is often connected to Oncology in his work. His studies in Gastroenterology integrate themes in fields like Survival rate, CHOP, Neutropenia, Peripheral T-cell lymphoma and Rituximab.
His Lymphoma research integrates issues from Stage and Positron emission tomography, Nuclear medicine. The various areas that he examines in his Follicular lymphoma study include Mantle cell lymphoma, Non-Hodgkin's lymphoma and B cell. His research in Diffuse large B-cell lymphoma intersects with topics in Testicular Involvement and Hazard ratio.
His scientific interests lie mostly in Internal medicine, Surgery, Oncology, Rituximab and Lymphoma. His Internal medicine study frequently involves adjacent topics like Gastroenterology. His studies deal with areas such as Hematology, Mantle cell lymphoma and Salvage therapy as well as Oncology.
His Rituximab research is multidisciplinary, incorporating perspectives in CHOP and Fludarabine. His research on Lymphoma also deals with topics like
His main research concerns Internal medicine, Oncology, Diffuse large B-cell lymphoma, Lymphoma and Rituximab. His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology. His study in Oncology is interdisciplinary in nature, drawing from both Refractory, Chemoimmunotherapy, Hematology, Ibrutinib and Salvage therapy.
His Diffuse large B-cell lymphoma study also includes fields such as
Mantle cell lymphoma and Locus most often made with reference to Cancer research,
Clinical trial, which have a strong connection to Family medicine. The study incorporates disciplines such as Cyclophosphamide, Progression-free survival, Chemotherapy, Bortezomib and B cell in addition to Lymphoma. His Rituximab study also includes
Vincristine which is related to area like Prednisone and International Prognostic Index,
Hazard ratio which intersects with area such as Randomized controlled trial and Surgery.
Internal medicine, Oncology, Diffuse large B-cell lymphoma, Rituximab and Gastroenterology are his primary areas of study. Umberto Vitolo studied Internal medicine and Surgery that intersect with Meta-analysis. His research integrates issues of Hematology, Salvage therapy, Ibrutinib and Chemoimmunotherapy in his study of Oncology.
He has included themes like Cell of origin, CHOP, Lenalidomide and Gene expression profiling in his Diffuse large B-cell lymphoma study. His Rituximab research is multidisciplinary, relying on both Vincristine, Progression-free survival and Hazard ratio. His research investigates the connection between Gastroenterology and topics such as Mitoxantrone that intersect with problems in Hematopoietic stem cell transplantation and Fludarabine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Follicular lymphoma international prognostic index.
Philippe Solal-Céligny;Pascal Roy;Philippe Colombat;Josephine White.
Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
Andrea Gallamini;Martin Hutchings;Luigi Rigacci;Lena Specht.
Journal of Clinical Oncology (2007)
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico;Monica Bellei;Luigi Marcheselli;Stefano Luminari.
Journal of Clinical Oncology (2009)
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
Andrea Gallamini;Caterina Stelitano;Roberta Calvi;Monica Bellei.
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H Tilly;M Gomes da Silva;U Vitolo;A Jack.
Annals of Oncology (2012)
Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group
E. Zucca;A. Conconi;T.I. Mughal;A.H. Sarris.
Journal of Clinical Oncology (2003)
Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
Franck Morschhauser;John Radford;Achiel Van Hoof;Umberto Vitolo.
Journal of Clinical Oncology (2008)
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Dreyling;M Ghielmini;S Rule;G Salles.
Annals of Oncology (2014)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge.
The Lancet (2019)
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Simonetta Viviani;Pier Luigi Zinzani;Alessandro Rambaldi;Ercole Brusamolino.
The New England Journal of Medicine (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: